CNBC
US · 1 hrs ago
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
—Quality
0Ratings
0Comments
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!